Moreover, this study provides the rationale to investigate whether PI3K inhibitors can be used in ER+ early breast cancer patients with activated PI3K pathway and upregulated BARD1/BRCA1 to increase their sensitivity to chemotherapy and radiotherapy, an approach that may increase the cure rate of those high-risk patients. This evidence concerns the gene BRCA1 and breast cancer.